Tumor Registry of Lymphatic Neoplasia

Chronic Lymphocytic Leukemia (CLL) Clinical Trial

— TLN-Registry  

Official title:

Epidemiological Registry Describing Treatment Reality and Therapy Modalities of Patients With Malignant Lymphatic Systemic Diseases (Non-Hodgkin`s Lymphoma, Chronic Lymphocytic Leukemia and Multiple Myeloma) Requiring Therapy.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00889798
• Other study ID #: IOM-TLN
• Status: Completed
• Start date: April 2009
• Est. completion date: August 31, 2019

Study information

• Verified date: May 2020
• Source: iOMEDICO AG
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

The purpose of this registry is to record information on therapy reality of malignant lymphatic systemic diseases by office-based haematologists in Germany.

Description:

The TLN is a prospective, longitudinal, nation wide cohort study with the purpose to record information on the antineoplastic treatment of lymphatic neoplasms in Germany. The registry will follow patients for up to five years. It will identify common therapeutic sequences and changes in the treatment of the disease. At inclusion, data in patient characteristics, comorbidities, tumor characteristics and previous treatments are collected. During the course of observation data on all systemic treatments, radiotherapies, surgeries, and outcome are documented.

The impact of nutrition (LyNut) and physical activity (LyNut) on the course of the adjuvant disease will be examined in patients with indolent and aggressive Non-Hodgin Lymphoma, as well as long-term effects of systemic treatment (LyTox) and quality of life (LyLife) in patients with multiple myeloma.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 3795
• Est. completion date: August 31, 2019
• Est. primary completion date: August 31, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Confirmed diagnosis of Non-Hodgkin`s lymphoma, chronic lymphocytic leukaemia or multiple myeloma

• Must receive a first- or second-line therapy

• 18 years or older

• Signed, written informed consent

Exclusion Criteria:

• no systemic therapy

Related Conditions & MeSH terms

• Chronic Lymphocytic Leukemia (CLL)
• Leukemia
• Leukemia, Lymphocytic, Chronic, B-Cell
• Leukemia, Lymphoid
• Lymphoma
• Lymphoma, Non-Hodgkin
• Multiple Myeloma
• Multiple Myeloma (MM)
• Neoplasms, Plasma Cell
• Non-Hodgkin's Lymphoma (NHL)

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
iOMEDICO AG

References & Publications (5)

Knauf W, Abenhardt W, Aldaoud A, Nusch A, Grugel R, Münz M, Hartmann H, Marschner N; TLN Study Group. Treatment of Non-transplant patients with multiple myeloma: routine treatment by office-based haematologists in Germany--data from the prospective Tumour — View Citation

Knauf W, Abenhardt W, Dörfel S, Meyer D, Grugel R, Münz M, Hartmann H, Marschner N. Routine treatment of patients with chronic lymphocytic leukaemia by office-based haematologists in Germany-data from the Prospective Tumour Registry Lymphatic Neoplasms. H — View Citation

Knauf W, Abenhardt W, Mohm J, Rauh J, Harde J, Kaiser-Osterhues A, Jänicke M, Marschner N; TLN-Group (Tumour Registry Lymphatic Neoplasms). Similar effectiveness of R-CHOP-14 and -21 in diffuse large B-cell lymphoma-data from the prospective German Tumour — View Citation

Knauf W, Abenhardt W, Slawik HR, Bückner U, Otremba B, Sauer A, Zahn MO, Wetzel N, Kaiser-Osterhues A, Houet L, Marschner N; TLN-Group (Tumour Registry Lymphatic Neoplasms). Rare lymphomas in routine practice-Treatment and outcome in Waldenström's macrogl — View Citation

Knauf W, Aldaoud A, Hutzschenreuter U, Klausmann M, Dille S, Wetzel N, Jänicke M, Marschner N; and the TLN-Group (Tumour Registry Lymphatic Neoplasms). Survival of non-transplant patients with multiple myeloma in routine care differs from that in clinical — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Course of treatment (treatment reality)	Documentation of anamnestic data and therapy sequences	5 years per patient
Secondary	Effectiveness of treatment	Documentation of response rates and progression-free survival per therapy sequence, overall survival time and adverse reactions	5 years per patient